Sign In
Buy JNJ
$241.00
+1.92 (+0.80%)
At Close: Jun 24, 2026
12 High-Yield Dividend Aristocrats To Weather The Coming 2025 Storm In Style
07:00am, Saturday, 07'th Dec 2024
The S&P is up almost 28% in 2024, and many investors worry about a melt-up followed by a sharp correction like in 2022 or 2018. A 2025 market correction is likely, but low-volatility, high-yield Divid
Johnson & Johnson Is A Better Dividend Stock Than Amgen In Our View
01:50pm, Friday, 06'th Dec 2024
Recent market concerns have pressured the stock prices of both Johnson & Johnson and Amgen Inc. In times of uncertainties, I go back to timeless insights like those offered by Peter Lync on dividend s
Johnson & Johnson (JNJ) Stock Slides as Market Rises: Facts to Know Before You Trade
06:45pm, Wednesday, 04'th Dec 2024
In the most recent trading session, Johnson & Johnson (JNJ) closed at $150.47, indicating a -1.24% shift from the previous trading day.
Dow 30 December Dogs Show 28 Pay Dividends And 1 "Safer" Buy
05:37pm, Wednesday, 04'th Dec 2024
Verizon is the only Dow Dog meeting the ideal of annual dividends from $1K invested exceeding its single share price. Five more Dow Dogs, including Cisco and Merck, are within 66% of meeting this idea
J&J Seeks FDA Approval for Tremfya for Psoriasis in Kids
10:01am, Tuesday, 03'rd Dec 2024
Johnson & Johnson JNJ announced that it has filed two supplemental biologics license applications (sBLA) seeking expanded use of its drug Tremfya in pediatric patients.
Investors Heavily Search Johnson & Johnson (JNJ): Here is What You Need to Know
02:30pm, Monday, 02'nd Dec 2024
Zacks.com users have recently been watching Johnson & Johnson (JNJ) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Johnson & Johnson seeks U.S. FDA approval for first pediatric indications for TREMFYA® (guselkumab)
08:00am, Monday, 02'nd Dec 2024
Applications filed for TREMFYA® to treat children with moderate to severe plaque psoriasis and active juvenile psoriatic arthritis SPRING HOUSE, Pa. , Dec. 2, 2024 /PRNewswire/ -- Johnson & Johnson
U.S. FDA Approves Biocon Biologics' YESINTEK™, Bmab 1200 Biosimilar to J&J's Stelara® (Ustekinumab)
07:00am, Monday, 02'nd Dec 2024
BRIDGEWATER, N.J. and BENGALURU, India , Dec. 2, 2024 /PRNewswire/ -- Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd (BSE code: 532523, NSE: BI
3 Fantastic Dividend Stocks to Buy Sooner Rather Than Later
05:52am, Sunday, 01'st Dec 2024
You don't have to be an income investor to like dividends. Many billionaires who definitely don't need income still have dividend stocks in their portfolios.
Forget Big Tech - I'll Take Dividend Stalwarts Any Day
07:30am, Friday, 29'th Nov 2024
Big Tech dominates markets but faces risks like slowing growth, AI dependency, and inflated valuations. Dividend stalwarts offer a safer, smarter alternative. Dividend stocks, like those in VYM and SC
How To Build A $25,000 Dividend Portfolio, Johnson & Johnson As Your Core Holding
03:00pm, Thursday, 28'th Nov 2024
Johnson & Johnson offers investors an effective combination of dividend income and dividend growth, evidenced by its Dividend Yield [TTM] of 3.13% and 5-Year Dividend Growth Rate [CAGR] of 5.61%. The
BMY Stock vs. JNJ Stock
05:00am, Wednesday, 27'th Nov 2024
Given its better prospects, we believe that Bristol Myers Squibb stock (NYSE: BMY) is currently a better pharmaceutical pick over Johnson & Johnson stock (NYSE: JNJ). BMY stock trades at 8.3x its forw
Strategic ETF Allocations: Enhancing Income, Diversification, And Reducing Risks In Your Dividend Portfolio
06:00pm, Tuesday, 26'th Nov 2024
I added shares of the Schwab U.S. Dividend Equity ETF and the Cohen & Steers Quality Income Realty Fund to The Dividend Income Accelerator Portfolio, boosting income and portfolio diversification. The
2 Very Healthy Dividend Stocks to Hold for Decades of Income
06:18am, Tuesday, 26'th Nov 2024
Checking a company's vital signs before investing in its stock for dividend income is essential. If the underlying company isn't financially healthy, its dividend probably won't last very long.
One Sector Has Underperformed Massively: These 4 Blue-Chip Dividend Giants Are Huge 2025 Plays
11:46am, Monday, 25'th Nov 2024
Key Points Donald Trump's victory is positive for the stock market.
